Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

2-(Thio-phen-2-yl)-1-(thio-phen-2-ylmeth-yl)-1H-benzimidazole.

ABSTRACT: In the title compound, C(16)H(12)N(2)S(2), the thio-phene groups are rotationally disordered over two sets of sites, by approximately 180°, with occupancy ratios of 0.916?(2):0.084?(2) and 0.903?(2):0.097?(2). The major components of the thio-phene and methyl-ene substituted thio-phene rings are canted by 24.06?(12) and 85.07?(10)°, respectively, from the benzimidazole ring system plane and the dihedral angle between the major component thio-phene ring planes is 84.90?(14)°. In the crystal, there is a weak C-H?N hydrogen bond which links mol-ecules into chains.

SUBMITTER: Geiger DK

PROVIDER: S-EPMC3275178 | biostudies-literature | 2012 Feb

REPOSITORIES: biostudies-literature

ACCESS DATA

Json Xml

Publications

2-(Thio-phen-2-yl)-1-(thio-phen-2-ylmeth-yl)-1H-benzimidazole.

Geiger David K DK Geiger H Cristina HC Williams Leo L Noll Bruce C BC

Acta crystallographica. Section E, Structure reports online 20120118 Pt 2

In the title compound, C(16)H(12)N(2)S(2), the thio-phene groups are rotationally disordered over two sets of sites, by approximately 180°, with occupancy ratios of 0.916 (2):0.084 (2) and 0.903 (2):0.097 (2). The major components of the thio-phene and methyl-ene substituted thio-phene rings are canted by 24.06 (12) and 85.07 (10)°, respectively, from the benzimidazole ring system plane and the dihedral angle between the major component thio-phene ring planes is 84.90 (14)°. In the crystal, ther ...[more]

PMID: 22347034

Similar Datasets

5-Bromo-2-(thio-phen-2-yl)-1-(thio-phen-2-ylmeth-yl)-1H-benzimidazole.

Project description:There are two independent mol-ecules in the asymmetric unit of the title compound, C(16)H(11)BrN(2)S(2). In the crystal, weak C-H?N hydrogen bonds and C-H?thio-phene ring inter-actions link the mol-ecules into chains along [100]. The structure exhibits disorder of the 2-thio-phen-2-yl substituent of one of the symmetry-unique mol-ecules with a major:minor component ratio of 0.914?(3):0.086?(3).

| S-EPMC3515228 | biostudies-literature

5-Chloro-2-(thio-phen-2-yl)-1-(thio-phen-2-ylmeth-yl)-1H-benzimidazole-6-chloro-2-(thiophen-2-yl)-1-(thiophen-2-ylmethyl)-1H-benzimidazole (0.94/0.06).

Project description:There are two independent mol-ecules in the asymmetric unit of the title compound, C16H11ClN2S2. The structure exhibits rotational disorder of the 2-thio-phen-2-yl substituent in each of the unique mol-ecules with a major:minor component ratio of 0.927?(2):0.073?(2). For one of the symmetry-unique molecules, 6.0?(2)% of the sites are occupied by the 6-chloro-isomer. The major component thio-phene rings make dihedral angles of 38.90?(12) and 36.32?(11)° with the benzimidazole rings in the two independent mol-ecules. In the crystal, mol-ecules are linked into chains parallel to [100] via weak C-H?N inter-actions.

| S-EPMC3790407 | biostudies-literature

6-Chloro-2-(thio-phen-2-yl)-1-[(thio-phen-2-yl)meth-yl]-1H-benzimidazole.

Project description:The title compound, C16H11ClN2S2, co-crystallizes with a small amount of the 5-chloro- isomer. The ratio of 6-chloro- to 5-chloro- isomers is 0.969?(2):0.031?(2). One thio-phen-2-yl substitutent displays rotational disorder with 80.6?(4)% of the mol-ecules exhibiting the major orientation. In the crystal, weak C-H?N and C-H?S hydrogen-bonding inter-actions result in chains of mol-ecules parallel to [001].

| S-EPMC3648326 | biostudies-literature

5,6-Dimethyl-2-(5-methyl-thio-phen-2-yl)-1-[(5-methyl-thio-phen-2-yl)meth-yl]-1H-benzimidazole.

Project description:The title mol-ecule, C20H20N2S2, is T-shaped and consists of a nearly flat 5,6-dimethyl-2-(5-methyl-thio-phen-2-yl)benzimidazole system approximately perpendicular to the 5-methyl-thio-phen-2-ylmethyl substituent. The 5,6-dimethyl-2-(5-meth-yl-thio-phen-2-yl)benzimidazole system is rotationally disordered about the two imidazole N atoms as approximated by a twofold rotation axis with a refined major/minor occupancy ratio of 0.884 (2):0.116 (2). The benzimidazole ring system is essentially planar, the largest deviations being 0.026 (2) and 0.044 (18) Å in the major and minor components, respectively. The inter-planar angles between the benzimidazole unit and the 5-methyl-thio-phen-2-yl substituent are 10.8 (3) and 8(3)° in the major and minor components, respectively, and the corresponding angles with the 5-methyl-thio-phen-2-ylmethyl substituent are 88.12 (8) and 89.5 (4)°. In the crystal, mol-ecules are oriented with their 2-(5-methyl-thio-phen-2-yl)benzimidazole mean planes approximately parallel to (11[Formula: see text]) and appear to be held together by π-π [2-thiophene⋯imidazole centroid-centroid distance = 4.1383 (7) Å] and C-H⋯π contacts. A weak C-H⋯N hydrogen bond generates infinite chains parallel to [100].

| S-EPMC3998620 | biostudies-literature

4-Bromo-2-(5-bromo-thio-phen-2-yl)-1-[(5-bromo-thio-phen-2-yl)meth-yl]-5,6-dimethyl-1H-benzimidazole.

Project description:The title compound, C18H13Br3N2S2, was obtained via the reaction of N-bromo-succinamide with 5,6-dimethyl-2-(thio-phen-2-yl)-1-[(thio-phen-2-yl)meth-yl]-1H-benzimidazole. The compound exhibits rotational disorder of the 5-bromo-thio-phen-2-yl substituent with a refined major:minor occupancy ratio of 0.876 (7):0.124 (7). The 5-bromo-thio-phen-2-yl mean plane is canted to the benzimidazole plane by 20.0 (4) and 21 (4)° in the major and minor components, respectively. In the crystal, weak C-H⋯N inter-actions link the mol-ecules into infinite C(7) chains along the 21 axes.

| S-EPMC3998606 | biostudies-literature

4-[2-(4-Meth-oxy-phen-yl)eth-yl]-3-(thio-phen-2-ylmeth-yl)-1H-1,2,4-triazol-5(4H)-one monohydrate.

Project description:In the title compound, C(16)H(17)N(3)O(2)S·H(2)O, the triazole ring makes a dihedral angle of 34.63 (6)° with the benzene ring. The thio-phene ring is disordered over two orientations [occupancy ratio = 0.634 (4):0.366 (4)] which make dihedral angles of 54.61 (16) and 54.57 (31)° with the triazole ring. Inter-molecular N-H⋯O and O-H⋯O hydrogen bonds stabilize the crystal structure.

| S-EPMC3238856 | biostudies-literature

4-[3-(1H-Imidazol-1-yl)prop-yl]-3-methyl-5-(thio-phen-2-ylmeth-yl)-4H-1,2,4-triazole monohydrate.

Project description:In the title compound, C(14)H(17)N(5)S·H(2)O, the triazole ring makes dihedral angles of 48.15?(8) and 84.92?(8)° with the imidazole and thio-phenyl rings, respectively. The water mol-ecule is involved in inter-molecular O-H?N hydrogen bonding.

| S-EPMC3011757 | biostudies-literature

2-[4-(1H-1,2,4-Triazol-1-yl)phen-yl]-1H-benzimidazole.

Project description:In the title compound, C(15)H(11)N(5), the benzimidazole ring system is nearly planar [maximum deviation = 0.039?(2)?Å], and is oriented at a dihedral angle of 28.85?(10)° with respect to the benzene ring; the dihedral angle between the triazole and benzene rings is 17.30?(15)°. In the crystal N-H?N hydrogen bonds link the mol-ecules into chains. Weak C-H?N inter-actions are also present.

| S-EPMC3470242 | biostudies-literature

2-(3,4,5-Trimethoxy-phen-yl)-1H-benzimidazole.

Project description:In the title compound, C(16)H(16)N(2)O(3), the dihedral angle between the mean planes of the aromatic ring systems is 30.90 (15)°. In the crystal structure, the mol-ecules form [010] chains by way of N-H⋯N hydrogen bonds.

| S-EPMC2961418 | biostudies-literature

2-(3,4-Di-fluoro-phen-yl)-1H-benzimidazole.

Project description:In the title mol-ecule, C13H8F2N2, the dihedral angle between the benzimidazole ring system and the di-fluoro-substituted benzene ring is 30.0?(1)°. In the crystal, mol-ecules are linked by N-H?N hydrogen bonds, forming chains along [010]. In addition, weak C-H?F hydrogen bonds connect chains into a two-dimensional network parallel to (001). A weak C-H?? inter-action is observed between an H atom of the benzimidazole ring sytem and the ? system of the di-fluoro-substituted benzene ring.

| S-EPMC3884342 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data